Intellia Therapeutics Head office building

Investors
& Media

Banner Menu

Press Releases

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Read More

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

Upcoming
Events

Stock Information

Minimum 15 minutes delayed. Source: LSEG